# A Single-Arm, Prospective Study of Papaverine for the Treatment of Refractory Peripheral Neuropathy Induced by Taxane-Based Chemotherapy

> **NCT07572461** · NA · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 43 (estimated)

## Conditions studied

- Chemotherapy-Induced Peripheral Neuropathy
- Refractory Chemotherapy-Induced Peripheral Neuropathy
- Paclitaxel-Induced Peripheral Neuropathy

## Interventions

- **DRUG:** Papaverine hydrochloride injection

## Key facts

- **NCT ID:** NCT07572461
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07572461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07572461, "A Single-Arm, Prospective Study of Papaverine for the Treatment of Refractory Peripheral Neuropathy Induced by Taxane-Based Chemotherapy". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07572461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*